公开(公告)号：US20230398228A1

公开(公告)日：2023-12-14

申请号：US18062996

申请日：2022-12-07

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/30 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32

CPC classification number: A61K47/6803 ,  C07K16/30 ,  A61K47/6889 ,  A61K47/6849 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

公开(公告)号：US20200297860A1

公开(公告)日：2020-09-24

申请号：US16702720

申请日：2019-12-04

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/30 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

公开(公告)号：US10322192B2

公开(公告)日：2019-06-18

申请号：US15892921

申请日：2018-02-09

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  A61K31/357

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

公开(公告)号：US20180193478A1

公开(公告)日：2018-07-12

申请号：US15892921

申请日：2018-02-09

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/28 ,  C07K16/32 ,  A61K31/357

CPC classification number: A61K47/6803 ,  A61K31/357 ,  A61K47/6849 ,  A61K47/6889 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.

公开(公告)号：US10548986B2

公开(公告)日：2020-02-04

申请号：US15448497

申请日：2017-03-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Earl F. Albone ,  Xin Cheng ,  Daniel W. Custar ,  Keiji Furuuchi ,  Jing Li ,  Utpal Majumder ,  Toshimitsu Uenaka

IPC: A61K47/68 ,  C07K16/30 ,  A61K31/357 ,  C07K16/28 ,  C07K16/32

Abstract: Linker toxins and antibody-drug conjugates that bind to human oncology antigen targets such as folate receptor alpha and/or provide anti-tubulin drug activity are disclosed. The linker toxins and antibody-drug conjugates comprise an eribulin drug moiety and can be internalized into target antigen-expressing cells. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the antibody-drug conjugates provided herein.